QCG
FATE icon

Quadrant Capital Group’s Fate Therapeutics FATE Stock Holding History

Quadrant Capital Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-349
Closed -$1.22K – 2756
2024
Q3 		$1.22K Buy
349
+81
+30% +$315 ﹤0.01% 2564
2024
Q2 		$880 Sell
268
-172
-39% -$753 ﹤0.01% 2576
2024
Q1 		$3.23K Buy
+440
New +$2.72K ﹤0.01% 2410
2023
Q3 		– Sell
-417
Closed -$1.99K – 2713
2023
Q2 		$1.99K Sell
417
-3,278
-89% -$18.1K ﹤0.01% 2417
2023
Q1 		$21.1K Buy
3,695
+2,956
+400% +$17.8K ﹤0.01% 1677
2022
Q4 		$7.46K Buy
739
+722
+4,247% +$13.6K ﹤0.01% 2084
2022
Q3 		$0 Sell
17
-17
-50% -$491 ﹤0.01% 2688
2022
Q2 		$1K Sell
34
-196
-85% -$5.41K ﹤0.01% 2359
2022
Q1 		$9K Buy
230
+190
+475% +$7.36K ﹤0.01% 1690
2021
Q4 		$2K Buy
40
+33
+471% +$1.87K ﹤0.01% 2124
2021
Q3 		$0 Buy
7
+1
+17% +$78 ﹤0.01% 2539
2021
Q2 		$1K Sell
6
-2
-25% -$161 ﹤0.01% 2254
2021
Q1 		$1K Buy
+8
New +$767 ﹤0.01% 2209

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Quadrant Capital Group's FATE Position: Q4 2024 in Review

Quadrant Capital Group sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 349 shares — an estimated $1.22K sold.

Quadrant Capital Group first reported a position in FATE in Q1 2021 and held it in 13 quarters. The position peaked at $21.1K in Q1 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Quadrant Capital Group reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 349 Fate Therapeutics shares in Q4 2024, an estimated $1.22K.
  • Quadrant Capital Group first reported a position in Fate Therapeutics in Q1 2021 and held it in 13 quarters.
  • Quadrant Capital Group's Fate Therapeutics position peaked at $21.1K in Q1 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.